Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is rare with a poor outcome and is resistant to conventional cytotoxic chemotherapy. The efficacy and safety of durvalumab and tremelimumab for treating recurrent or metastatic PSCs were assessed by a nonrandomized, open‐label, phase II study. METHOD...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Thorac Cancer
Huvudupphovsmän: Kim, Miso, Keam, Bhumsuk, Ock, Chan‐Young, Kim, Se Hyun, Kim, Yu Jung, Lim, Sun Min, Kim, Jin‐Soo, Kim, Tae Min, Hong, Sook‐Hee, Ahn, Mi Sun, Shin, Seong Hoon, Kang, Eun Joo, Kim, Dong‐Wan, Im, Sun‐Wha, Kim, Jong‐Il, Lee, Jong Seok, Kim, Joo‐Hang, Heo, Dae Seog
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons Australia, Ltd 2020
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7705626/
https://ncbi.nlm.nih.gov/pubmed/33026712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13684
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk